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Abstract 
 
Understanding the mechanisms of the experimental anti-cancer drug β-Lapachone 
is crucial for optimizing its mode of action - especially when it is used in conjunction 
with other treatment regimens, namely therapeutic radiation, due to possible interactions. 
It is our aim to exploit the knowledge gained from studying the interaction between β-
Lapachone and radiation for better tumor control. β-Lapachone is a novel anti-cancer 
compound that is activated intracellularly by the enzyme NAD(P)H:quinone 
oxidoreductase 1 (NQO1), which is over-expressed in many cancer cells. It has been 
reported that concentrations of NQO1 can be further up-regulated by various cellular 
stressors including radiation. Therefore radiation potentiates β-Lapachone’s cytotoxicity 
when radiation is used as a pre-treatment. Treating with β-Lapachone in fractionated 
radiation treatments, have been shown to suppress sub-lethal damage (SLD) repair of 
radiation damage. Therefore combined treatments of radiation and β-Lapachone have 
been observed to involve synergistic interactions based on two complementary actions: 
pretreatment of cancer cells with radiation to increase NQO1 which potentiate β-
Lapachone’s cytotoxicity and suppression of SLD repair by β-Lapachone post irradiation. 
In an attempt to illuminate important factors for designing an optimal treatment for solid 
tumor control, a deeper understanding of the interactions between the two treatments was 
needed, such as, the changes made in the cell cycle of several cell lines by various 
treatment combinations involving radiation and β-Lapachone, changes made in the 
concentrations of NQO1 pre/post-treatments involving β-Lapachone, and the impact of 
treatment on the tumor micro-environment in regards to in vivo tumor response to 
fractionated radiation in the presents of β-Lapachone. Our results shows a marked 
sensitization towards radiation of FSaII and A549 cells treated with β-Lapachone and a 
significant suppression of sub-lethal damage (SLD) repair. β- Lapachone’s cytotoxicity 
appears to be agnostic towards cell cycle phase and hypoxic cells. β- Lapachone has also 
been shown to be effective in delaying growth of FSaII tumors grown in C3H mice when 
treated in a single β-Lapachone dose and a single fraction of radiation as opposed to its 
fractionated regimen analog, and so placing it as a candidate for steriotatic body radiation 
therapy (SBRT) and steriotatic radiosurgery (SRS) combined treatments. 
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1 Introduction 
 
As one of the oldest documented diseases in history, cancer is first known to be 
described more than 5000 years ago (1), and is believed to have existed for all of human 
history. Hippocrates (ca. 460 BC – ca. 370 BC) however was responsible for coining the 
term. It is only in recent history, with the invention of the microscope and a fuller 
understanding of physiology, we understand the cellular basis of cause and progression of 
cancers and tumors. 
 
1.1 Cancer Prognosis with Radiation Therapy: Then and Now 
 
The established modalities of cancer treatment in medicine include localized 
treatments such as surgery and radiation therapy, and systemic treatments such as 
chemotherapy, hormonal therapy, autoimmune therapy, and radioactive particle uptake 
therapy. Surgery was the first modality used successfully in the treatment of cancer. As 
predictive abilities in relation to genetics and behavior are improved, prophylactic 
surgery has become a growing treatment path; notably women having a mutated BRCA-1 
gene being at high risk for developing breast cancer are electing to have a double breast 
mastectomy (2) (3). Unlike surgery, cancer treatment with chemotherapy is systemic and 
is the main treatment available for disseminated malignant diseases. A wide verity of 
chemical agents have been identified and successfully used to treat cancer. Two main 
classes of chemotherapeutic drugs are either cell cycle phase specific or phase non-
specific. In short, phase specific indicated that above a certain dosage level, further 
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increase in drug doesn’t result in more cell killing and in the case of phase non-specific, 
the drugs generally have a linear (or exponential) dose-response curve. As has been 
mentioned before, chemotherapy is a systemic treatment, as such the modality of choice 
for certain non-localized cancers among others, but this ability to have access to all 
cancerous cells in the body also means equal access to all health   cells, paving the way 
for unintended side-effects through the targeting of healthy cells. The side effects of 
many chemotherapy drugs are well known and documented, including nausea and hair 
loss being among the most notable. Of greater interest in this dissertation is the 
application of radiation for the treatment of tumors, notably its application in conjunction 
with chemotherapeutic agents. 
Radiation therapy is a local modality used in the treatment of cancer. Upon its 
discovery by Wilhelm Röntgen, “On a new kind of rays” (4), ‘x’-rays were very quickly 
exploited for its medical potential (5). Radiation therapy is one of the most important 
modalities for the treatment of cancer. According to the Physician Characteristics and 
Distribution in the U.S. (2008 Edition, 2004 IMV Medical Information Division, 2003 
SROA Benchmarking Survey), nearly two-thirds of all cancer patients received radiation 
therapy. In 2004, nearly one million patients in the U.S. were treated with radiation 
therapy, that sixty percent of the patients treated in 2004, or 574,930 individuals, had not 
previously received radiation therapy. In 2004 about 23.4 million patients visited 
hospitals and freestanding radiation therapy centers. Three cancers – breast cancer, 
prostate cancer and lung cancer – make up more than half (56 percent) of all patients 
receiving radiation therapy. For most cancer types treated with radiation therapy, at least 
75 percent of the patients are treated with the intent to cure the cancer, rather than control 
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the growth or relieve symptoms like pain. For lung and brain cancers, that number is 
somewhat lower, with 59 percent of lung cancer patients and 50 percent of brain cancer 
patients being treated with the goal of curing the cancer. In 2004, 88 percent of patients 
treated with radiation therapy received external beam x-rays treatments from a linear 
accelerator with more specialized radiation treatments such as Gamma Knife and 
brachytherapy (using radioactive sources) make up the remaining 12 percent. 
  Success of radiotherapy treatment largely depends on the differences in the 
radiosensitivity between the tumor and normal tissue and this will be discussed in detail 
below. Although x-rays are the primary radiation source for treatments, radionuclides 
have been used locally in the case of brachytherapy and gamma knife, and systemically 
to treat systemic malignant disorders. Of note in radionuclide systemic treatments, 
radioactive iodine is the treatment of choice for thyroid cancer while strontium-89 
tritiated with simple sugars is used for the treatment of metastasis. 
Prognosis due to medical intervention has been improving in recent years, though 
very slowly. Despite the wealth of knowledge regarding cancer, and improved detection 
and treatment, many types of cancers have hardly made a budge as far as the 5 year 
relative cancer survival rate. The relative cancer survival rate is a specific measurement 
of survival where the rate is calculated by adjusting the rate to remove all causes of death 
except cancer. It is the ratio of a cancer patient's chance of surviving a given time interval 
to that of an average person of the same age and sex (6). As can be seen in Figure 1.1.a, 
there haven’t been significant improvement in cancer mortality in relation to lung and 
bronchus cancers, where patients from 2003-2007 have not shown significant 
improvement above the last date points shown in Figure 1.1.a (6). On a positive note 
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however, while improvements in prognosis have incrementally improved, there is a 
steady and consistent increase in survival, indicating that, among other factors such as 
improved lifestyle and early detection, research efforts are having a positive impact on 
cancer prognosis. It is my hope that the work completed, as summarized by this 
dissertation, aids in this effort to improve and increase the scientific community 
understanding of cancer and its treatment. 
  
  
 
Figure 1.1.a Percent 5-year relative survival of lung and bronchus cancer 
patients. Source: Cancer Trends Progress Report—2011/2012 
Update, National Cancer Institute, NIH, DHHS, Bethesda, MD, 
April 2010, http://progressreport.cancer.gov 
 
 
1.2 Irradiation of Living Cells 
 
Radiation generally refers to the physical property of many different forms of 
energy departing an atom. One of two ways to broadly classify radiation is to consider 
whether the radiation has its origins within the nucleus or not, while the other being 
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whether it is a particle (Fermions) or an electromagnetic photon (Boson). 
 
Common Types of 
Radiation 
 
Atomic Source 
Fundamental Nature 
(Boson or Fermions) 
Alpha Nuclear Fermions 
X-rays Electronic Configuration Boson 
Beta Nuclear Fermions 
Neutron Nuclear Fermions 
Gamma Nuclear Boson 
 
Table 1.2.a. Examples of common types of radiation showing its respective 
atomic source and fundamental nature. 
 
When radiation interacts with a material other than its source, its energy 
determines whether it has the ability to ionize; namely have the energy to liberate an 
electron (or any other atomic component such as part of or the whole nucleus) from an 
atom or molecule. Radiation having sufficient energy to liberate parts of an atom from its 
original form, thereby creating charged particles, is known as ionizing radiation, 
conversely, radiation having only sufficient energy to change the energy states associated 
with the rotational, vibrational or electron valence configurations of atoms and 
molecules, is called non-ionizing radiation. 
Radiobiology seeks to understand the biologic response of living cells to ionizing 
radiation, and for practical considerations, the greatest emphasis have been placed on 
understanding the biologic response to therapeutically relevant radiation. Specifically, the 
entity within a cell that leads to the most significant biologic response is the DNA 
molecule. However, while x-rays dominate radiotherapy, technological improvements 
have made other radiation modalities more and more feasible. First example is fast 
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neutrons – the hammersmith cyclotron was suggested and conceived by Gray based on 
the notion that a lowered OER would be beneficial in radiotherapy. The cyclotron, 
however, suffered from the limitations of poor depth doses (equivalent to 250-kVp x-
rays) and a fixed horizontal beam. Cyclotrons built for neutron therapy achieved good 
dose depth but suffered from high radiation toxicity due to its high relative biological 
effectiveness. All had fixed horizontal beams, and all were located in physics building far 
away from patients. Boron-neutron capture theory – the idea is to deliver to the cancer 
patient a boron-containing drug that is taken up only in tumor cells and then exposes the 
tumor cells to sublethal neutron therapy. When the neutron interacts with the boron, the 
boron will emit densely ionizing short- range alpha particles to the tumor. However, to 
date there are no boron containing chemical agents that can be selectively up-taken into 
the tumor, additionally, low energy neutrons have poor depth doses. Protons – the OER is 
almost indistinguishable from that of x-rays. The dose deposited by a beam of protons 
increases slowly with depth, but reaches a sharp maximum near the end of the range of 
the Bragg peak. Proton beams ranging in energy from 150 to 200 MeV are of interest in 
radiotherapy because this corresponds to ranges of about 16-26 cm in tissue. Interest in 
carbon ion radiotherapy has been rekindled largely in Europe and Japan. The 
characteristic depth-dose profile of heavy ions, which is similar to that of protons, is very 
attractive for the radiotherapy of deep-seated tumors. The depth at which the peak occurs 
depends on the energy. The peak is so narrow that it must be ‘spread out’ by varying the 
energy of the beam. Compared with protons, carbon ions have less lateral scattering, 
leading to shaper beam edges. 
The amount of ionizing events within an irradiated cell is directly related to its 
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biologic response. Quantifying the amount of ionizing events within such a cell is known 
as the dose, which is the charge, measured in the SI unit of Coulomb (C), of the ionized 
particles produced per unit mass is the absorbed energy. The modern unit for measured 
absorbed energy in tissue is the Gray (Gy), which is defined as the 1 Joule (J) of 
deposited energy in 1 kilogram (kg) of tissue. The first unit for measuring dose was the 
roentgens (R) which was standardized to measurement of dose to air, where a conversion 
factor was needed to account for the dose to tissue (or any other target material), the 
resulting adjusting dose was known simply as the rad. 
1 
C
kg
 = 3876 R ≅ 3720.96 rad (in soft tissue) 
1 rad = 0.01 
J
kg
 = 0.01 Gy 
 The energy of the radiation needed to cause ionizing events is hard to define and 
quantify in the form of a dose, due to the fact that there are several different forms of 
ionizing radiations, that the specific type of interaction (photoelectric effect, compton 
scattering or pair production)  is radiation energy dependent in the case of photons, that 
the target material, more specifically living tissue, is comprised of a verity of atoms and 
molecules and as such have a range of ionizing energies, that the newly ionized charged 
particles go on the cause other ionizing events, etc., however, the first electronic ionizing 
energy for both hydrogen and oxygen (the atomic constitutions of water, where water is 
by orders of magnitude the most abundant molecule within a cell) are 14 eV, this can be 
considered the minimum incoming radiation energy each photon needs to cause an 
ionizing event in tissue. Simplifying this problem by assuming soft tissue to have a 100% 
composition of water, then determining the likelihood of interactions, and their frequency 
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can now more easily be determined. 
 
  
  
Table 1.2.b Relative importance of photoelectric (τ), Compton (σ), and pair 
production (π) in water (7). 
 
There are also marked differences in how a photon (X- ray) and a particle deposits 
their energy with-in tissue, where what distinguishes the two have biological 
implications. Radiation tend to have a more direct ability to ionize atoms or molecules 
which can cause a biologic effect, while photons tend to deposit its energy less frequently 
over a longer distance. 
 
 
 
Figure 1.2.c Visual depiction of the linear energy transfer (LET) per unit length 
among different types of radiation. Each dot indicates an ionizing 
event. Low LET radiation is considered lightly ionizing while high 
LET is considered densely ionizing. 
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While there are caveats regarding radiative LET, such as its energy deposition are 
distance-traveled dependent, the biologically relevant information relates to whether it is 
able to directly or indirectly ionize atoms or molecules which lead to biologically 
relevant changes. In the case of directly ionizing radiation, the probability that such a 
particle can ionize a cell’s atom or molecule leading to a biologic response is much 
higher than the case where the ionized product of a non-biologically relevant atom or 
molecule is itself the ionizing agent acting on a cell’s atom or molecule that has the 
potential of a biologic response, notably DNA. Most commonly, the indirect ionizing 
reaction achieves its energy deposition through the creation of free radical ions by the 
very ions created from ionizing intra-cellular water molecules. 
H2O +  ↯  →  𝐻2𝑂
+  + e− 
H2O +  𝐻2𝑂
+ →  H3O
+ + OH− 
When an incident externally originating x-ray photon having at least 14 eV 
(represented by “↯“) ionizes a water molecule, which constitutes 80% of a living cell, it 
may become ionized resulting in H2O
+ and a free electron would have been produced. In 
the case for H2O
+, if it meets another water molecule within its short lifetime of 10-10 
seconds, it can react with it to form a hydronium ion, H3O
+, and a highly reactive 
hydroxyl radical, OH-, which can diffuse more than twice the length of the diameter of a 
DNA double helix (8). 
Survival of Irradiated Cells 
Radiation damage to the DNA leads to a greater biological response, when 
compared to an equivalent radiation dose to other cellular organelles. It only takes 
between 1 and 2 Gy to cause sufficient DNA damage that will result in the loss of 
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clonogenic potential; where clonogenic potential refers to a cancerous cell’s ability to 
proliferate indefinitely. 
Irradiated cells die most often at mitosis (9) (10) (11) (12) (13). The best method 
for determining the effect of irradiation on cell survival is to measure the number of cells 
with the potential to divide indefinitely. That is, the ‘clonogenic assay’ is the best 
measure for cells with the potential to divide indefinitely, most importantly because this 
assay allows time for the survival cells to cycle through many cycles in an effort to 
separate the clonogenically viable cells from the mortally damaged cells that will survive 
for several generation but eventually die. 
According to target therapy, the survival of cells exponentially decrease with a linear 
increase in high-LET radiation dose, as such the surviving fraction (SF) of cells can be 
modeled as: 
 SF =  e−αD 
Where -α is the slope and D is the radiation dose, when the SF is plotted on a log 
scale. If we assume that each ionizing event results in loss of clonogenic potential and 
also assume that each cell has a single target (DNA), then we can use Poission’s statistics 
to determine the probability of an ionizing event that will lead to loss of clonogenic 
potential. 
𝑃(𝑛) =  
𝑒−𝑥𝑥𝑛
𝑛!
 
Where x is the average number of events and n is the specific number of events. 
(If each ionizing event results in loss of clonogenic potential (x = 1), then the probability 
of survival is the probability of not being ionized (n = 0). From the Poisson statistics we 
would have: 
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𝑃(0) =  
𝑒−1∙ 10
0!
 =  𝑒−1  = 𝑠𝑢𝑟𝑣𝑖𝑣𝑖𝑛𝑔 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 0.368 𝑜𝑟 ~37%  
If D0 = 1 / α, then 
SF =  e−αD =  𝑒−D/D0 
So when D0 = D, then  
 𝑒−1  = 𝑠𝑢𝑟𝑣𝑖𝑣𝑖𝑛𝑔 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 0.368 𝑜𝑟 ~37%.                            . 
Therefore, D0 is often called the mean lethal dose, or the dose that, on average, 
causes the loss of clonogenic potential per cellular target. 
In preparation for characterizing the radiation response of rodent fibrosarcoma 
cells (FSaII) of the C3H mice, the following clonogenic assay was performed. FSaII cells 
were harvested, using 0.25% of a digestive enzyme solution, trypsin, containing 
ethylenediaminetetraacetic acid (EDTA) for 5 minutes at 37ºC, while they were in an 
exponential growth phase, ensuring a normal distribution of cells in their various cell 
cycles. After cells have been detached from the culture flask, they were collected in 15 
ml tubes, centrifuged at 1500 rpm and the supernatant was removed, the cells were gently 
rinsed with a phosphate buffered solution (PBS), re-centrifuged at 1500 rpm and that 
supernatant was again removed. The FSaII cells were then resuspended in regular media 
containing Gibco's Rapid Prototyping & Manufacturing Institute medium (RPMI-1640), 
and supplemented with 10% fetal bovine serum (FBS) (PAA Laboratories, Inc., 
Etobicoke, Ontario), penicillin (50 U/ml), and streptomycin (50 µg/ml) – fetal bovine 
serum (FBS), a nutrient source, served here to neutralize the activity of trypsin. The 
cellular concentration in suspension was then determined using a hemocytometer. Known 
numbers of cells were then seeded on flasks and allowed to rest, giving time for the 
newly transplanted cells to adhere to the flask and resume its normal functions. This time 
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is typically 14-16 hours between seeding cells and irradiation, because enough time 
should be given for the cells to attach and resume its normal functions, but not so much 
time that cells begin dividing and as such increasing the number for cells being treated to 
an unknown number. For this experiment, the cells were irradiated using the Philips RT-
250 Orthovoltage external beam x-ray machine at 250 kVp (Philips Medical System, 
Brookﬁeld, WI), with added filtration of 1.0 mm Al and 0.35 mm Cu for the low energy 
x-rays, delivering at a dose-rate of approximately 1 Gy/minute. Various increasing doses 
of radiation were delivered in a single fraction, while having one group of flasks set aside 
to receive a 0 Gy dose, as the control group. The purpose of including controls is to 
determine what is known as the plating efficiency (PE). After irradiations, all cells were 
returned to an incubator for about 7-10 days. The colonies formed were rinsed with 
phosphate buffered saline, fixed with a mixture of methanol and acetic acid (10:1 v/v), 
stained (using 0.5% crystal violet and 25% methanol solution), rinsed in water, then 
allowed to dry in an oven overnight. Colonies with more than 50 cells were counted. An 
example of the stained colonies can be seen in Figure 1.2.d. 
 
   
 
Figure 1.2.d Image of stained macroscopically visible colonies of FSaII cells. 
The control flask was seeded with 100 cells while the radiation 
treated flasks were seeded with 1000 and 5000 FSaII cells 
respectively. 
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The plating efficiency of control cells was used to normalize the surviving 
fraction of irradiated cells. 
𝑃𝑙𝑎𝑡𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝑃𝐸)  =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
 
Next the surviving fraction (SF) is determined for all the treated groups, which is 
the number of colonies counted divided by the plating efficiency normalized number of 
cells seeded. 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑆𝑢𝑟𝑣𝑖𝑣𝑖𝑛𝑔 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 (𝑆𝐹)  
=  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑 × (𝑃𝐸 100⁄ )
 
The resulting survival fraction of FSaII cells exposed to x-rays can be seen in 
Figure 2.2.e (section A), where the SF is plotted on a log scale on the y-axis and the 
radiation dose is linearly plotted on the x-axis. 
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Figure 2.2.e Survival curve of FSaII cells to various doses of x-rays. Section A 
depicts the survival of FSaII cells after various integral doses of 
radiation in a single fraction. Section B highlights the characteristic 
biphasic nature of the survival slope in section A with its 
extrapolation lines. Section C depicts the resulting survival curve 
when the radiation dose greater than 2.5 Gy is split into two 
fractions where the first fraction is 2.5 and the second fraction 
being the difference between the first 2.5 Gy and the intended total 
dose. The second slope indicates that splitting dose increases the 
cell's ability to survive. Section D indicates the biphasic nature of 
the second fractionated curve, and its similarity in slope to the 
original single fraction curve. 
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According to the single ionizing event of a single target theory that was modeled 
with Poisson’s statistics, we expected only one straight line. However as can be seen by 
this curve, it is bi- phasic, meaning it is comprised of two different exponential functions 
which are extrapolated in section B, one exponential function representing the lower 
radiation doses {2} and the other representing the higher radiation doses {1}. The bi-
phasic curve therefore infers both a single ionizing event and multiple targets situation 
and multiple ionizing events for each target. In the first instance the equation, SF =
 e−αD, satisfies the case where a single ionizing event with multiple targets causes the 
loss of clonogenic potential while the equation, SF =  e−βD
2
, satisfies the case where 
multiple ionizing events with a single target causes the loss of clonogenic potential, with 
‘β’ representing the slope of that curve while the dose is squared. The combination of 
these two models is known as the linear-quadratic model. 
SFwhole curve  =  e
−αD−βD2 
Given that the ‘target’ of interest is DNA, when there is a loss of clonogenic 
potential, what is being referred to is the literal breaks or aberration in the chromosome 
due to radiation induced ionizations. In order to decrease the clonogenic potential of a 
cell, irradiation needs to produce double strand breakage (14) (15). In the case where a 
single ionizing event with multiple targets causes the loss of clonogenic potential, it 
refers to one ionizing event leading to a double strand break, and in the case where 
multiple ionizing events act on a single target, it also refers to a double strand break with 
contributions from independent ionizing events. 
 
 
 
SYNERGISTIC EFFECTS OF COMBINING THERAPEUTIC RADIATION AND β-LAPACHONE AGAINST TUMORS 
 
16 
 
2 Anti-Cancer Properties of Experimental Drug β–Lapachone 
 
2.1 β–Lapachone's Cytotoxicity 
 
β–Lapachone is a quinone-like compound found in the bark of the Lapachone 
trees (Figure A2), which are native to central south America, and have been used for 
hundreds of  years for its medicinal qualities, including but not limited to anti-bacterial, 
slowing age related degeneration and amelioration of obesity and related phenotypes in 
mice (55) (56). Importantly, β–Lapachone has recently been found to poses strong anti-
cancer properties. β–Lapachone's anti-cancer properties stem from the fact that it is 'bio-
activated' inside the cell by the enzyme NQO1 and its cytotoxicity is a result of several 
contributing factors, namely β–Lapachone's unique ability to generate reactive oxygen 
species. When β–Lapachone in its quinone form (β–Lap Q) enters cells, it is activated by 
the engyme NQO1 which reduces β–Lap Q with two electrons to β–Lapachone 
hydroquinone (β–Lap HQ) using NADH or NADPH as electron sources. However, β–
Lap HQ is an unstable molecule and spontaneously oxidizes back into its original β–Lap 
Q form. If β–Lap HQ oxidizes back to β–Lap Q one electron at a time, as opposed two 
electrons oxidization in a single step, there will be an intermediary form known as β–
Lapachone semiquinone (β–Lap SQ) is formed. When β–Lap HQ oxidizes via β–Lap SQ 
in the presents of cytosolic oxygen [O2], superoxides [O2-] and in turn hydrogen 
peroxides [H2O2] are formed. 
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Figure 2.1.a. Flow diagram showing NQO1 reducing β–Lapachone in the 
quinone form (β–Lap Q) to β–Lapachone in the hydroquinone 
form (β– Lap HQ) by use of NADH or NADPH electron donation. 
β–Lap HQ is unstable and under goes a single electron oxidation to 
a β–Lapachone semiquinone β–Lap SQ intermediary. When β–Lap 
HQ oxidizes back to β–Lap Q via β–Lap SQ in the presence of 
cytosolic oxygen, superoxides and hydrogen peroxide are 
generated. 
 
When β–Lapachone is oxidized back into its original quinone form, it is again 
available to be reduced by NQO1. As can be seen in Fig 2.1.a, β–Lapachone's changes 
from its quinone form to its hydroquinone from and back again to its quinone form, 
sometimes via its semiquinone form, and as such a futile cycling is initiated. It is this 
futile cycling that is responsible for β–Lapachone's cytotoxicity. It is proposed that this 
futile cycling severely depletes intra-cellular NADH and NADPH, which in turn depletes 
adenosine triphosphate (ATP) leading to increases in cytosolic 
Ca2+ released from the endoplasmic reticulum. Increased Ca2+ in the cytosol causes 
depolarization of the mitochondrial membrane leading to pore formation and release of 
sequestered cytochrome C which in turn leads to the activation of caspase 9 and the 
SYNERGISTIC EFFECTS OF COMBINING THERAPEUTIC RADIATION AND β-LAPACHONE AGAINST TUMORS 
 
18 
 
induction of apoptosis (57) (58). In conclusion, the cytotoxic effect of β–Lapachone 
stems from two mechanisms: formation of ROS and depletion of NADH and NADPH. β–
Lapachone's cytotoxicity can be measured in vitro by determining its clonogenic 
surviving potential. In order to determine the cytotoxicity of β–Lapachone, an in vitro 
experiment was set up using two different cell lines, concentrations of β–Lapachone and 
time for the cells to be exposed to it. 
 
 
 
Figure 2.1.b. Clonogenic survival curve of FSaII and A549 cells exposed to β–
Lapachone for different lengths of time at 5 and 10 µM. The 
Standard Error (which is smaller than the points) was calculated by 
dividing the sample standard deviation and the square-root of the 
number of experiments representing each data point. Source: 
Compiled experimental data from the Radiation Biology 
Laboratory at the University of Minnesota. 
 
 
Based on this result, the following pertinent conclusions can be drawn: 
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1. β–Lapachone’s cytotoxicity increases with exposure time to the cell, and so is 
time dependant. 
2. β–Lapachone’s cytotoxicity increases with its concentration, and so is not phase 
specific in vitro. 
 
 
2.2 NAD(P)H: quinone oxidoreductase 1 (NQO1) 
 
The NQO1 has been shown to be a detoxifying enzyme according to several 
studies (39) (44) (45) (46) (47). NQO1 is a cytosolic reductase which uses NADH or 
NADPH as an electron source (48) to reduce quinones to hydroquinones in a single two-
electron step, as can be seen in the flow diagram in Figure 2.2.a. 
 
 
 
Figure 2.2.a. Flow diagram showing normal NQO1 activity – reducing a 
quinone to a hydroquinone by use of NADH or NADPH electron 
donation. 
 
NQO1 concentration is high in cells requiring antioxidant protection, such as lung 
epithelial, breast and colon, and vascular epithelium to name a few (44) (49). 
Interestingly, many cancer cells also over-express NQO1, which opens the possibility for 
NQO1 mediated anti-cancer therapies (50) (51) (52). It has been shown that the levels of 
cytosolic NQO1 can be further up-regulated through various cell stressing mechanisms, 
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including treatments involving cisplatin, mild heating (mild-temperature hyperthermia) 
and ionizing radiation (53) (54). 
The purpose of this project was to understand how therapeutically relevant doses 
of ionizing radiation can influence NQO1 intracellular levels. In order to observe possible 
post- irradiation changes in the intra-cellular levels of NQO1, a protein immunoblot 
analysis was done on the A549 cells (human non-small-cell lung adenocarcinoma) at 
various time points after an exposure to 4 Gy in a single fraction. Below is a schematic 
representation of the major steps for a typical protein immunoblot assay. 
 
 
 
Figure 2.2.b. Flow diagram showing the main steps of the protein immunoblot assay. 
 
Experimental Determination of Changes to Intra-Cellular NQO1 Levels in Irradiated 
Cells 
 
A549 cells growing exponentially in vitro were harvested, using 0.25% of a 
digestive enzyme solution, trypsin, containing ethylenediaminetetraacetic acid (EDTA) 
for 5 minutes at 37ºC were used. After cells have been detached from the culture flask, 
they were collected in 15 ml tubes, centrifuged at 1500 rpm and the supernatant was 
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removed. The cells were then gently rinsed with a phosphate buffered solution (PBS), re-
centrifuged at 1500 rpm and that supernatant was again removed. The A549 cells were 
then resuspended in RPMI-1640 medium, and supplemented with 10% fetal bovine 
serum (FBS) (PAA Laboratories, Inc., Etobicoke, Ontario), penicillin (50 U/ml), and 
streptomycin (50 µg/ml). Fetal bovine serum (FBS), in addition to supplementing cellular 
nutrition, also serves to neutralize the activity of trypsin. The cellular concentration in 
suspension was then determined using a hemocytometer. Cells were then seeded on new 
growing flasks and allowed to rest, giving time for them to adhere to the flask and resume 
its normal functions. This time is typically 14-16 hours between seeding cells and 
irradiation, because enough time should be given for the cells to attach and resume its 
normal functions, but not so much time that cells begin dividing and as such increasing 
the number for cells being treated to an unknown number. After cells were exposed to 4 
Gy irradiation, they were returned to the incubator for: 0h (control), 2h, 4h, 8h, 12h, 24h, 
48h, 72h and 96h. When the end time points were reached, cells were removed from the 
incubator, rinsed twice with phosphate buffered solution (PBS), trypsinized with 0.25% 
trypsin solution containing ethylenediaminetetraacetic acid (EDTA) for 5 minutes at 
room temperature. The detached cells were collected in 15 ml tubes, centrifuged at 1500 
rpm for 5 minutes and the supernatent was removed gently rinsed again with PBS, re-
centrifuged and that supernatent was again removed. The cells, now collected into a 
pellet, were lysed with 100 µl of lysis buffer while 15 µl of protease inhibitor was added 
to protect cytosilic enzymes from being cleaved by proteasomes. The lysed cells were 
then kept at - 80 ºC until all the cells from each end-time point has been collected. The 
frozen (-80 ºC) cells were put on ice to slowly thaw, gently vortexed, and centrifuged at 4 
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ºC (in a cold room) at 14,000 rpm for 20 minutes. The NQO1 containing supernatant was 
then collected and transferred into respective tubes in preparation for a bicinchoninic acid 
(BCA) based general protein concentration analysis using protein standards for a protein 
concentration reference. For the BCA analysis, a 96 well plate was used to hold three 
duplicates of each of the samples and three duplicates of each of the protein standards 
with the following solution for each well having a final volume of 229 µl containing: 200 
µl of BCA solution – [1 gm sodium bicinchoninate, 2 gm sodium carbonate, 0.16 gm 
sodium tartrate, 0.4 gm NaOH, and 0.95 gm sodium bicarbonate, brought to 100 ml with 
distilled water and adjusted to pH 11.25 usuing 10  M NaOH] || 4 µl of cupric sulfate 
solution – [0.4 gm cupric sulfate (5x hydrated) in 10 ml distilled water] || 25 µl of protein 
sample solution – [88 µl of PBS and 12 µl of protein sample (supernatant)]. After all the 
samples were loaded into a 96 well plate, they were incubated for 30 minutes at 37 ºC. At 
the end of the incubation period, the plate was loaded onto a spectrophotometer and 
optical density was read at 562 nm. Optical densities of known protein concentrations 
were used to create a standard curve, as can be seen in Figure 2.2.c., against which the 
unknown protein concentrations of the experimental samples were determined. 
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Figure 2.2.c. Protein standard curve showing the resulting optical density as 
measured by the spectrophotometer against the average of three 
protein samples of known concentrations after 30 minutes of 
incubation in a bicinchoninic acid solution. The R2 coefficient of 
determination for this curve is 0.994, which is the statistical 
measure of how well the regression line approximates the real data 
points. 
 
In order to isolate the protein of interest, NQO1, protein samples were analyzed 
using gel electrophoresis. This technique differentiates protein based on their electric 
charge, where the quantity of the electric charge directly correlates with the mass of that 
protein – the smaller the proteins mass directly corresponds to a smaller net charge. 
Smaller messes of protein travel furthest through the gel compared to larger protein for 
the same period of time. In order to prepare samples for gel electrophoresis, the protein 
concentration of the sample protein was determined from measurements using the protein 
standard curve. Based on previous protein immunoblot trial experiments with the NQO1 
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protein, a total protein concentration of 15 µg and total volume of 30 µl were selected to 
be loaded into the wells of the gel. The finial volume was determined by combining 15 µl 
of sample buffer with the remainder of the volume comprising the volume of sample 
protein needed to have 15 µg of protein and the remainder of the volume being lysis 
buffer. To this finial concentration, β-mercaptoethanol was added to reduce the protein 
disulfide bonds. The 30 µl final solutions were placed in microtubes and heated for 5 
minutes at 100 ºC in a water bath. After the gels wells were carefully loaded – with the 
first well with 20 µl of rainbow protein marker, and the rest of the wells with the heated 
final solutions – the voltage was set to 50V for the first 30 minutes so that all protein 
containing samples entered the gel, and then switched to 100V for another 2 hours. 
After running the gel electrophorese, the proteins were then dispersed within the 
gel in a protein mass dependent manner. In order to detect our specific protein, all the 
protein were carefully transferred from the running gel to a polyvinylidene difluoride 
(PVDF) membrane at 4ºC at 400 mA for 1 hour, a process known as 'blotting'. Membrane 
containing protein was washed in tris-buffered saline containing Tween-20 (TBST) and 
then blocked using 5% milk dissolved in TBST for 1 hour at room temperature on a 
gentle rocker. The blocking solution was then discarded and a new blocking solution was 
added containing a mouse derived anti-NQO1 primary anti-body (1ºAB), acquired from 
Abcam plc (Cambridge, England). Our desired dilution was 1:1000 1ºAB solution to 
blocking solution, or 1 μl of 1ºAB solution (1 μg/μl) in 1 ml, which would give a desired 
1 μg/ml for a final concentration. 1ºAB solution was left rocking gently with the protein 
PVDF membrane overnight at 4 ºC. On the next morning, the 1ºAB was removed and the 
membrane was rinsed three times with TBST for 15 minutes each time at room 
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temperature on a rocker. Next, the membrane was blocked in a similar manner for 1 hour 
followed by adding transferring the membrane into a secondary anti-mouse alkaline 
phosphatase linked (AP) antibody (2ºAB-AP) solution for another hour. The 2ºAB-AP 
solution was diluted to 1:2000 2ºAB-AP solution to blocking solution, or 1 μl of 2ºAB 
solution (1 μg/μl) in 2 ml, which would give a desired 0.5 μg/ml for a final concentration. 
After 1 hour of incubation at room temperature on a rocker, the membrane was rinsed 
three times for 15 minutes each time with TBST. The membrane was allowed to dry and 
exposed to an electro-chemi-fluroluminescent substrate (ECF) for 4 minutes before 
scanning. The ECF caused the alkaline phosphatase attached to the anti-mouse antibody 
to florescent in the blue spectrum. Fluorescing membrane was imaged using the 
photometer Storm 860 Scanner. 
  
  
Figure 2.2.d. Film exposure showing relative levels of NQO1 in A549 cells. The 
0h group without radiation (control) and post-irradiation of 4 Gy at 
the following post-irradiation times: 2h, 4h, 8h, 12h, 24h, 48h, 72h 
and 96h. Also shown are levels of alpha-tublin for each sample. 
 
As can be seen in Figure 2.2.d., levels of NQO1 began to rise as early as 4 hours 
post irradiation and reached a maximum at about 24 hours and remains elevated for more 
than 72 hours later when compared to the un-irradiated cells. Based on this result, the 
following conclusions can be drawn: 
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3. Levels of NQO1 are up-regulated by ionizing radiation of 4 Gy. 
4. Levels of NQO1 remains at elevated for more than 72 hours after 4 Gy. 
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3 Radiation and β–Lapachone Synergism 
 
The combination of therapeutically relevant radiation treatments and β–
Lapachone treatments shows that there is biologically measurable interaction between the 
two, in that each treatment modality complimentary potentiates the cellular lethality of 
the other. 
 
3.1 Complimentary Potentiating Mechanisms 
 
As has been previously discussed, radiation and other cell stressing modalities 
(59) up- regulates the concentrations of NQO1 enzyme, which may lead to cell death. 
However, in addition to this mechanism, it has been observed, and described below, that 
β–Lapachone enhances the sensitivity of cells to radiation. The following is a description 
of β–Lapachone’s radiation sensitizing effects. 
A549 and FsaII cell lines were used to access the effect of combined radiation and 
β–Lapachone treatments on cancer cells in vitro. The aim of this study was to determine 
whether β–Lapachone increases A549 cells sensitivity to radiation. In preparation, the 
cells were gently harvested, counted and appropriately plated into t-25 flasks in 
duplicates of three for each data point, from a healthy exponentially growing stock. Cells 
were plated for three treatment groups: 'Radiation only' group where cells were irradiated 
in single fraction, 'Drug only' group that was further split into two sub groups each 
receiving different concentrations of β–Lapachone, and the 'Combined radiation and drug 
group' for each radiation dose point. In the radiation only group, the dose point of 0 Gy 
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served as a global control for plating efficiency, the drug only group served as a control 
for the combined treated group, for the respective β–Lapachone concentration. β–
Lapachone concentrations of 5 µM and 2.5 µM were prepared by adding 2.423 grams to 
10 ml of supplemented media to make a 1 mole stock – 15 µl of the stock solution was 
added to 3 ml of supplemented media to make the working solution of 5 µM – some of 
the 5 µM working solution was diluted with supplemented media by a factor of 2 to get 
the working solution of 2.5 µM. Both the radiation only groups and the combined treated 
groups were irradiated with their respective doses in a single fraction. Immediately after 
irritation, combined treated groups and drug only groups were treated with β–Lapachone 
for 2 hours at their respective concentrations in an incubator, then all groups were gently 
rinsed with phosphate buffered saline (PBS) twice before adding supplemented media 
and returning them to an incubator for about 7- 10 days or until there are colonies visible 
to the eye. At this point, colonies were rinsed with sterile saline, fixed with a mixture of 
methanol and acetic acid (10:1 v/v),  and stained using 0.5% crystal violet solution in 
25% methanol for another 10 minutes, rinsed in water, then allowed them to dry in an 
oven overnight. Colonies containing more than 50 cells were counted. The average of the 
triplicate for each data point was determined and divided by the number of cells plated 
for that respective data point, for determination of the fractional survival of the cells. The 
normalized survival was determined by dividing the fractional survival of that data point 
by the fractional survival of the 0 Gy control; the normalized survival of the global 
control is consequently 1. Next, the combined treated group was normalized for the toxic 
effects of β-Lapachone action only by dividing the fractional survival of the combined 
treated groups by their respective drug concentrations of the fractional survival of the 
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drug only group. 
 
 Drug Normalized Survival Combined Treated Group = 
Fractional Survival of Combined Treated Group
Fractional Survival of Drug Only Group
 
This data was then plotted and can be seen in Figure 3.1.a. 
 
 
 
Figure 3.1.a. A549 cells treated with radiation alone or in combination with β–
Lapachone. A characteristic radiation survival curve is shown for 
cells receiving only radiation, while cells that were treated with β–
Lapachone for 2 hours immediately after irradiation shows a 
marked increase in sensitivity. An increase in sensitivity to the 
effects of radiation can be observed in correlation with an increase 
in β–Lapachone’s concentration from 2.5 µM to 5 µM. 
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As can be seen, the normalized combined treated groups showed increased 
radiation sensitivity by β–Lapachone in a drug concentration dependent manner. In order 
to better understand how the cells became sensitive to radiation, it is important to 
understand the possible effects β–Lapachone may have on the cell's normal ability to 
repair itself after radiation- induced ionizing stress to the DNA; specifically, of interest is 
whether β–Lapachone sensitizes cells to radiation by suppressing 'sub-lethal damage' 
repair. 
Sublethal damage repair is the operational term that describes increase in cell 
survival when a given radiation dose is split into two (or more) parts by a time interval. A 
dose of radiation lethal to a cell when delivered in a single fraction may not be lethal if 
the radiation dose is split into two fractions separated by a certain period of time; because 
some of the damage to the DNA is repaired during the time between radiation exposures. 
The splitting of a radiation dose is called fractionation; the greater the amount of time 
between fractions, the more the damaged DNA is repaired up to a threshold where any 
additional time given for repairs would not increase the odds of survival. After radiation 
exposure, various cell cycle checkpoint genes are activated, which brings about cell cycle 
arrest – allowing time for the repair of damaged DNA. If the inter-fraction time is 
sufficiently long, damage repair continue through the cell cycle checkpoints. 
Experimentally, the extent of sublethal damage repair can be quantified. The ratio of the 
number of surviving cells, resulting from the fractionated dose can be compared to the 
number of surviving cells, resulting from the same dose given in a single fraction. This is 
called the recovery factor. In vivo experiments show a clear suppression of sublethal 
damage repair for hypoxic tumors (18). This is clinically relevant because the cancer cells 
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comprising a tumor become hypoxic at only 70-80 µm away from blood vessels in part 
due to the diffusion limit of oxygen and the very high metabolism of each cancer cell. 
However it is important to note that hypoxic cells have an increased ability to survive a 
single fraction of radiation dose in comparison to a normoxic cell. The ratio of doses 
necessary to produce the same level of cell killing under hypoxic to aerated conditions is 
called the oxygen enhancement ratio. 
In order to address the question of whether β–Lapachone sensitizes cells to 
radiation by suppressing 'sublethal damage' repair, FSaII cells were divided into four 
groups as follows: 'Radiation only' group where cells were irradiated in single fraction, 
'Fractionated radiation only' group where cells were irradiated in two fractions with 2 
hours separating the two fractions, 'Drug only' group receiving 2.5 µM of β-Lapachone 
for 2 hours, and the 'Combined fractionated radiation and drug group' where cells were 
treated with β–Lapachone for two hours following the second fraction of radiation. In the 
radiation only group, the dose point of 0 Gy served as a global control for plating 
efficiency, the drug only group served as a control for the combined fractionated 
radiation and drug group. 
The radiation only group was irradiated with various doses in a single fraction. 
The fractionated radiation only group and combined fractionated radiation and drug 
group also received its first fraction of radiation at this time, starting at the 2.5 Gy dose 
point, for all total dose end points. All cells of both the fractionated radiation only group 
and the combined fractionated radiation and drug groups were returned to the incubator 
for the 2 hours inter- fraction time. After 2 hours, both the fractionated radiation only 
group and the combined fractionated radiation and drug groups received the second 
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fraction of radiation; the dose of the second fraction was determined by subtracting 2.5 
Gy of the first fraction from the total intended dose. The drug only and combined 
fractionated radiation and drug groups were then treated with 
2.5 µM of β–Lapachone for 2 hours and returned to an incubator. After 2 hours of β–
Lapachone treatment, all four groups were gently rinsed with phosphate buffered saline 
(PBS) twice before adding normal supplemented media and incubated for 7-10 days. 
Colonies were rinsed with sterile saline, fixed with a mixture of methanol and acetic acid 
(10:1 v/v), stained, rinsed in water, and then allowed to dry in an oven overnight. 
Colonies comprising more than 50 cells were counted. The normalized survival and the 
drug normalized combined treated group were determined and described in similar 
manner above, and are graphically represented in Figure 3.1.b below. 
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Figure 3.1.b. Survival of FSaII cells after various doses of radiation in one or 
two fractions. A characteristic radiation survival curve is shown for 
cells receiving only radiation, while cells that were treated with β–
Lapachone for 2 hours immediately after a second fraction of 
irradiation shows a marked increase in sensitivity even after 
normalizing for the effect of β–Lapachone alone due to 
suppression of SLD repair. All cells received a total of one fraction 
for doses 2.5 Gy and lower, while doses larger than 2.5 Gy 
received a total of two radiation doses where the first dose totaling 
2.5 Gy and the second dose being the difference needed to achieve 
the intended total dose. Cells receiving 2.5 µM of β–Lapachone 
were drugged for 2 hours following the second fraction of 
radiation. 
 
As can be seen in Figure 3.1.b, the survival curve of cells receiving radiation only 
in a single fraction shows a D0 value of 2 Gy. In the survival curve of cells receiving two 
exposures of radiation, a clear survival increase can be observed over the single fraction 
radiation only curve, indicating a sublethal damage repair. The combined treated group 
where cells were irradiated identically to the split dose radiation only group, and were 
then treated with 2.5 µM of β–Lapachone for 2 hours, were normalized for the 
independent influence on these cells from the 2.5 µM of β–Lapachone for 2 hours alone, 
and plotted. The survival curve, of cells treated with both 2.5 µM of β–Lapachone and 
two exposures of radiation, showed significant cell lethality when compared to its 
counterpart, the split dose radiation only curve. Additionally, this combined treated group 
showed a lower survival than that of the single fraction radiation only curve. This suggest 
that not only was there suppression of sublethal damage repair with a nominal treatment 
of β–Lapachone after the second fraction of radiation, but there even was increased 
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sensitivity beyond the suppression of repair as indicated by the fact that the combined 
curve was steeper than that of the radiation only single fraction curve. In further analysis 
of the effects of β–Lapachone’s sublethal damage repair suppression, the fractionated 
radiation dose was held constant while varying the inter-fraction time from 1 - 5 hours, in 
the presents of 2.5 µM of β–Lapachone during the entire inter-fraction time. Three groups 
were set-up as follows: 'Fractionated radiation only' group, where cells were irradiated in 
two equal fractions with a total dose of 5 Gy, 'Drug only' group receiving 2.5 µM of β–
Lapachone for the entire inter-fraction period, and the 'Combined fractionated radiation 
and drug group' where cells were drug treated for the entire inter-fraction time following 
the first fraction of radiation. In the radiation only group, the dose point of 0 Gy served as 
a control for plating efficiency, the 5 Gy dose point served as the point at which 
fractionated survival is compared, and the drug only group served as a control for the 
combined fractionated radiation and drug group. For this experiment, cells and β–
Lapachone concentration of 2.5 µM were prepared similarly to the previous experiment. 
On the day of treatment, the fractionated radiation only group and the combined 
fractionated radiation and drug group were irradiated at 2.5 Gy for the first fraction. The 
combined fractionated radiation and drug group and the drug only group were then 
treated with a β–Lapachone solution of 2.5 µM for the duration of the inter-fractionated 
period of 1 – 5 hours at 1 hour increments. All cells were then returned to the incubator 
for their respective inter-fraction time. After the inter-fraction time was completed, both 
the fractionated radiation only group and the combined fractionated radiation and drug 
groups received the second fraction of radiation, gently rinsed with phosphate buffered 
saline (PBS) twice, and cultured in regular media for  about 7-10 days or until there are 
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colonies visible to the eye. Colonies were rinsed with sterile saline, fixed with a mixture 
of methanol and acetic acid (10:1 v/v), and stained using 0.5% crystal violet solution in 
25% methanol for another 10 minutes, rinsed in water, then allowed to dry in an oven 
overnight. Colonies comprising more than 50 cells were counted. After all data for the 
treatment groups were normalized for plating efficiency, and the combined treated group 
was normalized for each respective drug only, the recovery factor was determined by 
comparing the normalized survival of all dose points receiving fractionated irradiation to 
the survival of cells receiving a single fraction dose (of 5 Gy). 
Recovery Factor =  
Normalized Survival of Data Point
Normalized Survival of Single Fraction Data Point
 
This experiment was repeated 6 times and was again repeated 7 times using the 
A549 cell line, where A549 cells received a total dose of 6 Gy, split into two equal 
fractions and FSaII cells received a total of 5 Gy split into two equal fractions. The 
recovery factor for fractionated radiation only group and the drug normalized combined 
fractionated radiation and drug group were determined and graphically represented in 
Figure 3.1.c below. 
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Figure 3.1.c. FSaII and A549 cells were irradiated with 5 Gy and 6 Gy 
respectively in a single dose or in two equal doses (2.5 Gy + 2.5 
Gy) and (3 Gy + 3 Gy) respectively, separated by different time 
intervals in the absence or presence of 2.5 µM β–Lapachone. The 
survival of FSaII cells irradiated with 5.0 Gy given in two doses of 
2.5 Gy progressively increased as the time interval between the 
two doses was increased up to 2 hours, demonstrating the sublethal 
damage caused by the first 2.5 Gy irradiation was repaired within 2 
hours. When cells were maintained in 2.5 µM β–Lapachone, the 
split-dose effect was markedly suppressed. The combine effect was 
normalized for the cytotoxicity of 2.5 µM β–Lapachone. A549 
shows similar results. These findings demonstrated that β–
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Lapachone significantly suppressed the repair of sublethal 
radiation damage. 
 
As can be seen in both FsaII and A549, the single fraction dose has a recovery 
factor of 1. As expected for recovery factor curves, the first 2 hours are the most critical 
period in which the majority of cells with sublethal DNA damages do most of its 
necessary repairs, after which point, allowing the cells additional repair time would only 
very modestly increase its viability. In both cases, the recovery has been suppressed even 
after accounting for the independent cytotoxic activities of β–Lapachone alone; 
consequently indicating suppression of the cell's ability to repair radiation induced 
sublethal damage to its DNA. Upon closer examination, the dose point at 5 Gy for the 
Figure 3.1.b, and the 2 hour inter-fraction time on Figure 3.1.b for the FsaII curve on 
appearance received very similar treatments, in that for both the fractionated radiation 
treatments, inter-fraction time, drug time and the drug concentration were identical, 
however, the drug treatment occurred after the first fraction of radiation in Figure 3.1.c 
and in Figure 3.1.b, the drug treatment occurred after the second fraction of radiation. In 
both cases, the drug normalized fractionated radiation (2.5 Gy – 2 hours – 2.5 Gy) cells 
had a lower survival that the single fraction radiation only (5 Gy), and much lower 
survival than the fractionated radiation only cells. Additionally, a marginal decrease in 
the cell's viability could be observed for the cells treated with β–Lapachone during the 
inter-fraction period as opposed to those that were treated after the second fraction, based 
on direct comparison at this dose point; consequently, suppression by β–Lapachone on 
the sublethal damage incurred by the first fraction of radiation is more effective than the 
suppression by β–Lapachone on the sublethal damage incurred by the first fraction of 
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radiation. In both cell lines however, it is clearly observed that even in the drug 
normalized combined treated groups, the cell viability increased with increased inter-
fraction time suggesting other mechanisms at play. In the recovery of the combined 
groups there are competing mechanisms influencing the viability of the cells, the cell's 
natural ability to repair radiation induced sublethal DNA damage – which increases 
survival – and the cytotoxicity of β–Lapachone – which decreases survival. In the first 
two hours after the first fraction of radiation and β–Lapachone treatment, both 
mechanisms compete and influence the cell's viability, however, after 2 hours, the effects 
of sublethal damage repair significantly decreases while the cytotoxicity of β–Lapachone 
continually increases due to the complimentary action of radiation's up-regulation of 
activating enzyme, NQO1; therefore accounting for the relatively high drug normalized 
recovery factor of this group for inter fraction times greater than 2 hours. 
 
Based on these results, the following conclusions can be drawn: 
 
5. There is significant suppression of sublethal damage repair with a nominal 
treatment of β–Lapachone after the second fraction of radiation; moreover, there 
is increased sensitivity beyond the suppression of repair, which suggests other 
cellular mechanisms at play. 
6. Suppression of sublethal damage repair is more effective when β–Lapachone is 
administered following the first fraction of radiation as opposed to the second 
fraction of radiation, where β–Lapachone's concentration and treatment times are 
equal. 
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3.2 β–Lapachone's Influence on the Cell Cycle 
 
Understandings of the cell cycle are very important objectives in cancer research. 
In this study, which will be described in detail, it shows that the A549 cell cycle is indeed 
altered when treated with β–Lapachone, irradiation and their various combinations. More 
importantly, it is experimentally shown that there are evident differences in the 
proportions of cells in the various parts of the cell cycle after treating with 7.5 µM of β–
Lapachone only and 4 Gy of radiation only. Furthermore, the proportions of cells in the 
various parts of the cell cycle of those treated with both 7.5 µM of β–Lapachone and 4 
Gy of radiation more closely resemble those that received 7.5 µM of β–Lapachone only, 
indicating β–Lapachone's influence over irradiation as it relates to the cell's ability to 
cycle through its phases. 
 
Cell Line Investigated and its Normal Environment 
 
The A549 (Human lung adenocarcinoma epithelial cell line) was used exclusively 
for these experiments and was originally acquired from the American Type Culture 
Collection (Manassas, VA). 
 
Treatment and Collection 
 
For each experiment, t-25 flasks, each containing 0.5 x 106  cells, were divided 
into four groups (Control, Radiation, Drug only, and Combination) where each group 
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contained one flask for each designated end time point: 6, 12, 24, 36 and 48 hours. The 
selected radiation and drug dose and drug treatment duration for the treated groups were 
chosen, based on numerous past experiments, because the expected number of surviving 
cells would be numerous enough for statistical significance (>10,000 cells after flow 
cytometric gating – discussed below) while having a cell lethality which is greater than 
50 percent for each treated group. The Drug 
only group received 7.5 µM of β–Lapachone and was left in the incubator for 1 hour after 
which it was gently rinsed twice with Dulbecco’s Phosphate Buffered Saline (DPBS) 
before being returned to the incubator. The combination group first received 7.5 µM of 
β–Lapachone and was then immediately irradiated with 4 Gy in a single fraction and then 
returned to the incubator for 1 hour after which it was gently rinsed twice in DPBS before 
being returned to the incubator. The radiation only group received 4 Gy in a single 
fraction and then returned to the incubator. The radiation and control groups were also 
gently rinsed with DPBS in a similar fashion and time as the other two groups to preserve 
experimental homogeneity. At each end time point, attached and floating cells from the 
appropriate flasks were collected in 15 ml tubes using 0.25% Trypsin with EDTA, 
centrifuged, resuspended in DPBS, centrifuged again and the supernatant was removed 
leaving only the cell pellet. The pellet was resuspended in 3 ml of 70% -20°C Methanol 
by slowly adding the methanol to the cell pellet and stored at 4°C for as short a time 
period as experimentally possible so that all time points have been reached or up to a 
week. 
 
 
SYNERGISTIC EFFECTS OF COMBINING THERAPEUTIC RADIATION AND β-LAPACHONE AGAINST TUMORS 
 
41 
 
Flow Cytometry and Data Analysis for Cell Cycle Determination 
 
After all the pellets for each end time point were frozen, the pellets from each 
group were thawed and collected by centrifuging the tubes and aspirating out the 70% 
methanol solution. Each pellet was then washed with 500 µl of DPBS and transferred to a 
microtube, centrifuged and resuspended in 0.525 ml of RNase/PI solution (0.125 mg 
RNase, 25 µl Propidium Iodide, 
0.5 ml DPBS). Cells were then left protected from light at room temperature for 30 
minutes to incubate. Next, each cell sample was filtered with a 70 µm sieve to separate 
still attached cells and analyzed by the flow cytometer for the relative concentration of 
DNA in each cell. For each cell sample, gating was used to exclude cell doublets, 
necrotic cells and other debris, while the retained cells were used to determine the 
proportions of cells in either G1, S, G2 or A (cells in  the M phase were included in G2). 
The cell cycle distributions were analytically determined  using the Dean-Jet-Fox 
mathematical modeling algorithm contained in the flow cytometry analysis software 
FlowJo (Tree Star, Inc. OR), which assumes that the S-phase can be modeled by a second 
degree polynomial (flowjo.com/v762/en/ccmodels.html), while having the constraint that 
G2 needs to have twice as much DNA as G1. Those results were plotted as a histogram, 
as can be seen in Figure 3.2.a. The average of six experiments were used to determine the 
correlation coefficients between the combination group and each of the other three groups 
using a simple Pearson's Correlation; results of which can be seen in Table 3.2.c. 
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Figure 3.2.a. Histogram of the 10,000 cells within the gated portions of the total 
cell population for the four groups at the 12 hour post-treatment 
end time. Intensity of PI, which directly correlates with amount of 
DNA, is shown on the x-axis and the number of events (single 
intact cells) on the y-axis. M1, M2, M3 and M4 mark the 
approximate boundaries for G1, S, G2 and A cell phases 
respectively. 
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Figure 3.2.b. [A.] State of the cell cycle after 12 hours of treatment. At this time point, 
the correlation between the combination group and the radiation only 
group is the lowest for the 12 hour time point (r=0.4475). The correlation 
between the combination group and the drug only group is high 
(r=0.9953), as is the correlation between the combination group and the 
control (r=0.9995). [B.] State of the cell cycle after 48 hours of treatment. 
At this time point of 48h, the correlation between the combination group 
and the radiation only group is the highest for the 48h post-treated 
collection times (r=0.9633). However, the correlation between the 
combination group and the drug only group is even higher (r=0.9874), 
followed by the correlation between the combination group and the control 
(r=0.9688). 
 
Pearson's Correlation Coefficient “r” 
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Table 3.2.c. The Pearson’s Correlation Coefficients between the proportion of 
cells in the various parts of the cell cycle, (G1, S, G2 and A) 
between the combination group and each of the other groups for 
each end time point. Numbers in bold and underlined shows the 
highest correlation for that end time point. 
 
For all the post-treatment collection times, the proportions of cells in the various 
parts of the cell cycle, including apoptotic cells, for the combination group more closely 
followed those of the drug only group than those of the radiation only group. The 
following conclusions can be drawn from the results: 
 
7. A population of A549 cells treated with 7.5 µM of β–Lapachone only modestly 
alters the proportions of cells in the various parts of the cell cycle, such as 
increased proportion of cells in the S-phase, when compared to untreated cells. 
8. There is significant cell cycle arrest in A549 cells after irradiation of 4 Gy within 
the first 24 hours, however when cells are also under the influence of 7.5 µM of 
β–Lapachone, there is no discernible arrest in the cell cycle. 
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  Given that Propidium Iodide was only used to quantify DNA content, pre-
apoptotic cells would have been included in the G1, S, and G2 data shown in Figure 3.2.b 
in unknown proportions. Additionally, the flow cytometer calculates proportions based 
on the analysis of the first 10,000 gated events (which usually correspond to single cells), 
however it was observed that the pellet size of all β–Lapachone treated groups from 12 
hours onwards were approximately half the size as those that did not receive β–
Lapachone. This can be due to cell shrinkage or to cell degradation due to apoptosis, and 
as such the actual proportion of cells undergoing apoptosis cannot be stated with 
accuracy based on this study. To better understand the sensitivity of β–Lapachone and 
Radiation on each of the A549 cell cycle phase, a more accurate assessment of apoptosis 
was needed. 
 
Determining Relative Pre-Apoptotic Activity for Each Cell Cycle Phase 
 
In order to determine whether apoptosis occurred more often in certain parts of 
the cell cycle, the pre-apoptotic activities were measured along with the relative 
concentration of DNA. The caspases 3 and 7, which were used as the pre-apoptotic 
markers, were detected using a Fluorochrome-Labeled Inhibitors of the activated form of 
Caspases 3 and 7 (FLICA) reagent kit (Immunochemistry Technologies LLC, 
Bloomington MN). Caspases 3 and 7 were chosen because they are effector caspases, and 
their activated forms preclude the final steps in the apoptotic pathway where the cell 
dismantles the DNA and arrest general metabolic activity leading to the cell's death. The 
FLICA reagent is based on a membrane-permeable carboxyfluorescein linked peptide 
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sequence which only covalently binds to the activated caspases 3 and 7. FLICA freely 
diffuses across the cell wall and specifically binds to caspases 3 and 7 – upon washing; 
the unbound FLICA diffuses out of the cell so that the remaining bounded FLICA is a 
direct measure of the caspases 3 and 7 activity at the time of inoculation. The pellets of 
the treated cells were resuspended in 0.5 ml of serum free media containing 10 µl of 
FLICA working solution (50 µl DMSO + 200 µl PBS + FLICA reagent) and incubated 
for 1 hour while being protected from light. Cells were centrifuged and washed three 
times using phosphate buffered saline to rinse unbounded FLICA reagent, centrifuged 
and the supernatant was again carefully removed. Next the pellets were resuspended in 
0.525 ml of RNase/PI solution (0.125 mg RNase, 25 µl Propidium Iodide, 0.5 ml DPBS) 
for DNA staining. Cells were incubated in dark for 30 minutes at room temperature. 
Next, each cell sample was filtered through a 70 µm sieve to separate attached cells and 
analyzed by the cytometer. Cells were not fixed after it was experimentally observed to 
reduce detection using the flow cytometer, and as such, special care was used to keep 
them cool while trying to minimize the overall time for labeling the cells. Untreated cells 
which did not receive either the FLICA reagent or DNA PI labeling [FL-PI-] were used 
as a double negative control in order to set the parameters for either keeping or excluding 
cells to be analyzed – specifically, electronically gating only whole intact single cells 
through the use of the forward and side scatter detectors, and as such exclude all the other 
detected events by the flow cytometer, as can be seen in Figure 3.2.d. 
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Figure 3.2.d. Gating of whole intact cells using the forward scatter channel 
(FSC-H) and side scatter channel (SSC-H) detectors. 
  
In order to determine background levels of the pro-apoptotic markers caspases 3 
and 7, untreated cells were prepared as described above with the FLICA reagent but 
without PI [FL+PI-]. Untreated cells were also used to determine background levels of 
the pro-apoptotic markers caspases 3 and 7 without using the FLICA reagent but with PI 
[FL-PI+]. Untreated cells receiving both the FLICA reagent and PI [FL+PI+], were used 
to determine the normal cell cycle distribution and the normal proportion of pre-apoptotic 
cells with active caspases 3 and 7 with-in each cycle. These untreated double positive 
controls were then compared with cells that were treated with 7.5 µM of β–Lapachone for 
1 hour at 24 hours post-treatment. 
Before levels of activated caspase activity were determined, whole intact cells 
were gated using the forward and side scatter detectors. Next, all sub-G1 cells 
representing post-apoptotic cells and cellular fragments were excluded, in addition to all 
doublets, triplets and any macromolecules containing more PI-stained DNA than cells in 
G2. Based analysis of the [FL- PI+] cells, 101 on the FL1-H y-axis, representing intra-
cellular FLICA concentration, has been chosen as the threshold value below which any 
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detected signal can be attributed to background processes either by normal cellular 
fluorescent activity or detector noise. The double positive controls [FL+PI+] had about 
45% of activated caspases 3 and 7 while the drug only [FL+PI+] cells, treated with 7.5 
µM of β–Lapachone for 1 hour followed by 24 hours of being drug-free under ideal cell 
culturing conditions, had about 80% (or about a 78% increase above control level) of 
activated caspases 3 and 7. 
  
 
 
Figure 3.2.e. Graph showing number of detectable FITC events per cell on the 
FL1-H y-axis, and length of PI stained DNA on the FL2-H axis 
where just over 200 marks the G1 cell cycle peak. [A.] FITC 
negative and PI positive whole and intact untreated control cells 
showing most cells below 101 on the FL1-H FITC y-axis, 
therefore 10 or fewer detectable FITC events per cell on the FL1-H 
detector is considered to be background signal. [B.] FITC positive 
and PI positive whole and intact untreated control cells showing 
about 45% of the cells having activated caspases 3 and 7. [C.] 
FITC positive and PI positive whole and intact 7.5 µM β–
Lapachone treated control cells showing about 80% of the cells 
having activated caspases 3 and 7, which is a 78% increase above 
control levels. 
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Next, the cell cycle distribution of the double positive controls and the drug 
treated cells were analytically determined using the Dean-Jet-Fox mathematical modeling 
algorithm (as described and referenced prior), while having the constraint that G2 needs 
to have twice as much DNA as G1. Summary of the cell cycle distribution for six 
independent experiments are presented in Figure 3.2.f. 
  
 
Figure 3.2.f. Comparison of the average percent cell cycle of FITC positive 
drug treated cells with the average percent cell cycle distribution of 
double positive untreated controls. N=6. Percent sub G1 not 
shown. 
 
As can be seen, the cell cycle distribution of the cells in the early stages of 
apoptosis as determined by levels of activated caspases 3 and 7 is comparable to the cell 
cycle distribution of untreated controls. Therefore, based on these added results, another 
conclusion can be drawn from these results: 
 
9. β–Lapachone's cytotoxic effects appears to be cell cycle phase independent. 
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3.3 Tumor Response 
 
Given that a fraction of tumor cells in vivo are hypoxic cells, the possible 
differential effect of β–Lapachone between normoxic cells and hypoxic cells were 
studied in vitro. 
                                . 
 
 
Figure 3.3.a. Normalized survival of A549 cells under normoxic and hypoxic 
conditions with and without the presence of 5 µM of β–Lapachone. 
The general agreement between the expected additive effects in the 
combined treated group and the actual results of the combined 
treated group suggest that there is no synergy in cell killing 
between hypoxic cells and β–Lapachone. 
 
For this experiment, creating a hypoxic environment proved to be a challenge. 
After much experimentation, it was observed that using glass flasks instead of the usual 
plastic flasks resulted in the best results in creating and maintaining a hypoxic 
environment for cultured cells. A549 cells were grown on the flat surface of specially 
designed glass tubes, which provided an elongated culturing surface. Known numbers of 
cells were seeded and maintained in regular media for 14-16 hours. A sterilized air-tight 
rubber stopper, used to cover the opening of the glass tube, was perforated by two large 
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gauged hypodermic needles. A mixture of 95% nitrogen and 5% CO2 air was used to 
aerate the inside of the tubes through one of the needles while the other needle served as 
an outlet for neutralizing the pressure within the tubes. Positive flow into the tubes from 
the 95% nitrogen and 5% CO2 air ensured that there was no backflow of oxygenated 
ambient air. This air exchange process was done continuously for 30 minutes to ensure a 
through expulsion of oxygen within the tubes. A visual observation of increased acidity, 
as a result of anaerobic respiration and lactic acid production, was made by the change in 
the media color towards light yellow due to the presence of phenolsulfonphthalein (a 
color pH indicator). Seven groups were established, where each data point for each 
experiment represents a duplicate of two flasks: a control group receiving no drug and 
remained in a normoxic environment, two hypoxic groups where one group maintained a 
hypoxic environment for 6 hours and another maintaining a hypoxic environment for 24 
hours, two drug only groups, both receiving 5 µM of β–Lapachone one for 6 hours and 
the other for 2 hours, and finally a combined group receiving 24 hours of continuous 
hypoxic environment followed by 6 hours of β–Lapachone at 5 µM, and the other group  
receiving 6 hours of continuous hypoxic environment followed by 2 hours of β–
Lapachone at 5 µM. The tubes were rapidly reoxygenated using a 50 cc gauge syringe to 
expedite air exchange at the onset of administering the drug. Combined treated groups 
and drug only groups were treated with 5 µM of β–Lapachone for their respective drug 
times in an incubator, then all groups were gently rinsed with phosphate buffered saline 
(PBS) twice before adding supplemented media and returning them to an incubator for 
about 7-10 days. This experiment was repeated six times for significance. After 
clonogenicity was determined for each group, data were normalized to controls, as can be 
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seen in Figure 3.2.c. The expected combined groups “Ex. Combo” was determined by 
multiplying the fractional survival of the hypoxic groups with the respective drug treated 
groups. The survival of the actual combined treated groups was in good agreement (with-
in each other’s respective standard error margins), suggesting that the effects of rapidly 
reoxygenated cells following a course of chronic hypoxia and the effects of 5 µM of β–
Lapachone were only additive. 
 
Based on this result, the following conclusion can be drawn: 
 
10. β–Lapachone’s cytotoxicity exhibits no cell killing synergy in vitro with cells that 
were recently reoxygenated following chronically hypoxic conditions. 
 
Effect of β–Lapachone and X-irradiation on tumors 
 
In order to determine the effect of β–Lapachone on murine tumors, FSaII cells 
were prepared for inoculation to ~20 gram C3H mice (The Jackson Laboratory, Bar 
Harbor, Maine). All studies were done in strict accordance of University of Minnesota 
Institutional Animal Care and Use Committee (IACUC). Exponentially growing cells 
were harvested and suspended in serum-free medium to a final concentration of 4x106 
cells in 1 ml. Each mouse received 2x105 cells in 50 µl subcutaneously into the right hind 
leg. When tumors grew to a diameter of about 5-7 mm, mice were separated into groups: 
control, drug only, x-irradiation only and combined drug and x-irradiation treatments. 
Mice that were treated with drug received an intraperitoneal  injection of β–Lapachone 
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diluted in Hydroxypropyl Beta Cyclodextrin (HPβCD) (60) solution to a concentration 
sufficient to inject 50 mg/kg of β–Lapachone in 200 µl of cocktail solution. Mice that 
were x-irradiated were first anesthetized using a cocktail of ketamine (100 mg/kg) and 
xylazine (10 mg/kg) diluted in sterile saline. We preferred an injectable volume of 0.2 ml 
per mouse which weighed ~20 gram, so the working solution of 4 ml of ketamine (100 
mg/kg) + 2 ml of xylazine (10 mg/kg) + 34 ml sterile saline was used and stored in 
rubber sealed blood tubes. After mice were anesthetized, they were loaded unto specially 
designed holders which provided for the tumor bearing legs to be positioned away from 
the rest of the body and exposed to a single fraction of 20 Gy at a dose-rate of 
approximately 1.5 Gy/minute. Lead shielding (4 mm thick) was used to protect the mice 
from the x-irradiation except for the area around the tumor. Analgesics or antibiotics 
were added to the drinking water post-treatment as warranted to keep the animal 
condition within the limits of the criteria for euthanasia. Tumor volumes were calculated 
using the formula: 
𝑉𝑜𝑙𝑢𝑚𝑒 =  
𝑎2𝑏
2
 
Where ‘a’ was the shortest tumor diameter and ‘b’ was the longest tumor diameter 
measured. Measurements were recorded using a caliper. Tumor volumes were measured 
every other day and the results were plotted in Figure 3.3.b. 
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Figure 3.3.b. Growth delay of FSaII tumors grown in C3H mice. Time for the 
tumor to grow and increase its volume fivefold (or about 800 
mm3) was about 7 days in the control, 9 days in the 50 mg/kg of 
β–Lapachone group, 15 days in the 20 Gy x-irradiation only group 
and about 22 days in the combined treated group. (Data points are 
means of 7–10 tumors ± 1 S.E) The difference between the 
radiation only group and the combined treated 
group (16 days v.s. 22 days), was statistically significant 
(P<0.001). Source: Compiled experimental data from the Radiation 
Biology Laboratory at the University of Minnesota. 
 
Untreated control tumors grew in an expected exponential-like manner. Those 
treated with both 20 Gy of x-irradiation and 50 mg/kg of β–Lapachone showed a marked 
and sustained delay of growth when compared to tumors treated with either 50 mg/kg of 
β–Lapachone or 20 Gy only suggesting increased cell killing due to the complimentary 
mechanisms discussed.  However, cells which are most sensitive to radiation within a 
tumor are the cells that are closest to a reliable blood supply and oxygen, so similarly, the 
hypoxic cells which are more radio- resistant to radiation treatments are for the same 
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reason the cells which tend to be out of reach of β-Lapachone. As such, how our tumors 
responded to a fractionated regimen of β–Lapachone and radiation was of interest. In 
order to investigate this question, another experiment was repeated to observe the tumor 
response to fractionated combined treatments. FSaII tumors of about 5-7 mm were 
divided into four groups: control, fractionated drug only, fractionated x-irradiation only 
and combined fractionated drug and x-irradiation treatments. The 20 Gy radiation 
treatments was  split into 4 equal parts of 5 Gy each fraction and delivered to the tumor 
bearing hind legs every other day. 50 mg/kg of β–Lapachone was given to the drug only 
and the combined treated groups 30 minutes before each radiation treatment. Tumor 
volumes were measured every other day, on the same days as irradiation. The relative 
volumes of the tumor growth were determined by dividing the measured volumes for 
each reading by the initial volumes measured on ‘Day 0’. These results were plotted in 
Figure 3.3.c. 
 
   
 
Figure 3.3.c. Tumor growth delay in FSaII tumors grown in C3H mice. Time for 
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the tumor to have an eightfold increase was about 9 days in the 
control, 12 days in the 50 mg/kg of β–Lapachone group, and about 
16 days for both the 20 Gy (5 Gy x 4 fractions) x-irradiation only 
group and the combined fractionated treated group. (Data points 
are means of 7–10 tumors ± 1 S.E). Arrows represent treatment of 
5 Gy x-irradiation and 50 mg/kg of β–Lapachone. 
  
As can be seen, an even greater tumor control was not observed for a treatment 
involving fraction when compared to a single treatment, and was unexpected based on the 
in vitro studies. Fearing experimental error, this study was very carefully repeated with 
very similar results. Given that the combined group showed no difference in tumor 
control than the radiation only group, it was suspected that there was no increased 
sensitivity due to the fact that the drug was not effective in consecutive treatments. Given 
that the activating enzyme NQO1 is upregulated upon cellular stress such as ionizating 
radiation, and consequently potentiates β–Lapachone’s cytotoxic effects, perhaps the 
concentrations of the enzyme is not regenerated in as high numbers as its first cell 
stressing event, or its concentration is reduced based on its initial interaction with β–
Lapachone. In either of those two scenarios, a lower concentration of NQO1 during the   
second, third and fourth treatments would consequently reduce β–Lapachone’s cytotoxic 
potential. In order to determine if enzymatic activity is affected following an initial 
treatment of β–Lapachone, an immune western blot study was performed for the 
detection of NQO1 in a post treated cell. After a through literature search, the 
predominant focus has been towards treatments which would show an increase in NQO1, 
as opposed to what happens to the cellular concentrations after a treatment with β–
Lapachone. 
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Figure 3.3.d Western blot analysis for NQO1. At 0h, cells that received either 4 
Gy or 4 Gy and 10 μM of β– Lapachonewere irradiated. Cells that 
received either 10 μM of β– Lapachone or 4 Gy and 10 μM of β– 
Lapachone were then treated  with 10 μM of β– Lapachone for 1 
hour, washed, and incubated at 37ºC under the standard culture 
conditions. At the indicated end time points after β–Lapachone 
treatment, cells were collected for western blot analysis. Blots 
were labeled with anti-NQO1 antibody and then with a horseradish 
peroxidase- conjugated secondary antibody, and visualized using 
chemiluminescence. 
 
Possible NQO1 depletion after treatment with β–Lapachone was studied. The 
following experiment was performed using A549 cells. 
 
Control       [collect cells] [Western Blot] 
4Gy       [Incubate 2 hours]   [collect cells] [Western Blot] 
4Gy       [Incubate 4 hours]   [collect cells] [Western Blot] 
4Gy       [Incubate 8 hours]   [collect cells] [Western Blot] 
4Gy       [Incubate 12 hours]   [collect cells] [Western Blot] 
4Gy       [Incubate 24 hours]   [collect cells] [Western Blot] 
4Gy       [Incubate 48 hours]   [collect cells] [Western Blot] 
4Gy       [Incubate 72 hours]   [collect cells] [Western Blot] 
4Gy       [Incubate 96 hours]   [collect cells] [Western Blot] 
10 μM (1 hour)     [Rinse then incubate 2 hours] [collect cells] [Western Blot] 
10 μM (1 hour)     [Rinse then incubate 4 hours] [collect cells] [Western Blot] 
10 μM (1 hour)     [Rinse then incubate 8 hours] [collect cells] [Western Blot] 
10 μM (1 hour)     [Rinse then incubate 12 hours] [collect cells] [Western Blot] 
10 μM (1 hour)     [Rinse then incubate 24 hours] [collect cells] [Western Blot] 
10 μM (1 hour)     [Rinse then incubate 48 hours] [collect cells] [Western Blot] 
10 μM (1 hour)     [Rinse then incubate 72 hours] [collect cells] [Western Blot] 
SYNERGISTIC EFFECTS OF COMBINING THERAPEUTIC RADIATION AND β-LAPACHONE AGAINST TUMORS 
 
58 
 
10 μM (1 hour)     [Rinse then incubate 96 hours] [collect cells] [Western Blot] 
4Gy + 10 μM (1 hour)    [Rinse then incubate 2 hours] [collect cells] [Western Blot] 
4Gy + 10 μM (1 hour)    [Rinse then incubate 4 hours] [collect cells] [Western Blot] 
4Gy + 10 μM (1 hour)    [Rinse then incubate 8 hours] [collect cells] [Western Blot] 
4Gy + 10 μM (1 hour)    [Rinse then incubate 12 hours] [collect cells] [Western Blot] 
4Gy + 10 μM (1 hour)    [Rinse then incubate 24 hours] [collect cells] [Western Blot] 
4Gy + 10 μM (1 hour)    [Rinse then incubate 48 hours] [collect cells] [Western Blot] 
4Gy + 10 μM (1 hour)    [Rinse then incubate 72 hours] [collect cells] [Western Blot] 
4Gy + 10 μM (1 hour)    [Rinse then incubate 96 hours] [collect cells] [Western Blot] 
 
After cells were collected, a western blot analysis was performed to observe the 
relative concentrations of NQO1 in the post-treated cells. As has been described 
previously, the cells were collected and analyzed as discussed prior. The results can be 
seen in Figure 3.3.d. The cells treated with both 10 μM of β–Lapachone for 1 hour and 4 
Gy of irradiation showed marked reduction in NQO1 levels for up to 24 hours, while 10 
μM of β–Lapachone for 1 hour alone and 4 Gy of irradiation showed unchanged levels of 
NQO1 and a slight increase in NQO1 respectively. 
 
Based on these results, the following conclusions can be drawn: 
 
11. β–Lapachone caused murine tumor growth delay. When used with radiation the 
tumor growth delay was very pronounced indicating that synergistic effects are at 
play. 
12. Fractionated use of β–Lapachone in combination with radiation does not have a 
potentiating effect. 
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13. NQO1 levels are depleted immediately after treatment of β–Lapachone and 
irradiation in A549 cells. Given β–Lapachone’s lack of synergy with radiation 
when fractionated, it may be a better candidate for steriotatic body radiation 
therapy (SBRT) and steriotatic radiosurgery (SRS) as opposed to prolonged 
fractionated regimens. 
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4 Conclusion 
 
The following is a summary of pertinent findings collected through laboratory 
experimentation, and its implications in treating tumors in combination with 
therapeutically relevant radiation therapy. Moreover, the following will propose how to 
lever0age these findings towards developing a new therapeutic alternative using β–
Lapachone and therapeutic radiation for the treatment of solid tumors. 
 
4.1 Summary of Findings and Implications 
 
1. β–Lapachone’s cytotoxicity increases with exposure time to the cell, and so is 
time dependant. 
2. β–Lapachone’s cytotoxicity increases with its concentration, and so is not phase 
specific in vitro. 
3. Levels of NQO1 are up-regulated by ionizing radiation of 4 Gy. 
4. Levels of NQO1 remains at elevated for more than 72 hours after 4 Gy. 
5. There is significant suppression of sublethal damage repair with a nominal 
treatment of β–Lapachone after the second fraction of radiation; moreover, there 
is increased sensitivity beyond the suppression of repair, which suggests other 
cellular mechanisms at play. 
6. Suppression of sublethal damage repair is more effective when β–Lapachone is 
administered following the first fraction of radiation as opposed to the second 
fraction of radiation, where β–Lapachone's concentration and treatment times are 
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equal. 
7. A population of A549 cells treated with 7.5 µM of β–Lapachone only modestly 
alters the proportions of cells in the various parts of the cell cycle, such as 
increased proportion of cells in the S-phase, when compared to untreated cells. 
8. There is significant cell cycle arrest in A549 cells after irradiation of 4 Gy within 
the first 24 hours, however when cells are also under the influence of 7.5 µM of 
β–Lapachone, there is no discernible arrest in the cell cycle. 
9. β–Lapachone's cytotoxic effects appears to be cell cycle phase independent. 
10. β–Lapachone’s cytotoxicity exhibits no cell killing synergy in vitro with cells that 
were recently reoxygenated following chronically hypoxic conditions. 
11. β–Lapachone caused murine tumor growth delay. When used with radiation the 
tumor growth delay was very pronounced indicating that synergistic effects are at 
play. 
12. Fractionated use of β–Lapachone in combination with radiation does not have a 
potentiating effect. 
13. NQO1 levels are depleted immediately after treatment of β–Lapachone and 
irradiation in A549 cells. Given β–Lapachone’s lack of synergy with radiation 
when fractionated, it may be a better candidate for steriotatic body radiation 
therapy (SBRT) and steriotatic radiosurgery (SRS) as opposed to prolonged 
fractionated regimens. 
 
Many of the findings are tacitly in agreement with literature, while adding to the 
body of scientific knowledge. This work clearly demonstrates that the effect of novel 
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anticancer drug β– Lapachone against mouse FSaII fibrosarcoma and human A549 lung 
cancer is potentiated by therapeutically relevant radiation. Importantly, we also found 
that β-lap treatment applied soon after irradiation inhibits the repair of sub-lethal 
radiation damage (SLD) as demonstrated by the changes in the shape of radiation 
survival curve. This understanding is based on experiments which shows β–Lapachone-
induced SLD repair was inhibited using split-dose radiation studies. Moreover, β–
Lapachone inhibition of the repair of sub-lethal damage caused by ionizing irradiation 
offers a complimentary mechanism which is greater than additive in cell lethality. These 
findings, as summarized above demonstrate that NQO1 plays central role in the β–
Lapachone-induced cell death. On its own, β–Lapachone has cytotoxic effects after it is 
activated by NAD(P)H:quinine oxidoreductase and then enters into a futile cycling 
between the original oxidized form of β–Lapachone and its two-electron reduced forms. 
The cycling between the oxidize and reduced forms of β–Lapachone generates reactive 
oxygen species (ROS), thereby causing DNA damages, depletion of NAD+ and ATP, 
Ca2+-dependent PARP-1 hyperactivation, loss of mitochondrial membrane potential, loss 
of Ca2+ homeostasis, inhibition of NFkB, degradation of p53 and activation of u-calpain 
(59) (60) (49) (53). NQO1 activity in tumors is significantly higher than those of non-
cancerous normal tissues by as much as 100-fold (60) (61) (62), indicating tumors will be 
preferentially targeted by β–Lapachone’s cytotoxic activities. The expression of NQO1 
gene is mainly regulated by the antioxidant response element (ARE) and has been shown 
to be activated by chemical induced oxidative stress, mild temperature hyperthermia and 
ionizing radiation (54) (55). Unlike radiation, β–Lapachone appears to be cell cycle 
agnostic in terms of its cytotoxicity, however its action has dramatic control over 
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radiation induced cell cycle check points, as was observed by the strong corelation 
between cells treated with β–Lapachone only and β–Lapachone combined with radiation. 
In addation, the cell cycles of cells treated with β–Lapachone closely mirrors that of 
untreated control cells. It also appears to be largely unaffected by whether a cell was 
previously hypoxic or whether a cell have always been in a normoxic environment. 
Considerations for β–Lapachone‘s cytotoxicity in cells currently under hypoxic 
conditions were not evaluated due to unfeasibility of the drug reaching the hypoxic cells 
in a tumor, by the very nature of why some cells are hypoxic. This is in contrast to 
irradiation studies where cells outside of a sufficiently reliable blood supply are still of 
consideration when attempting to understand its response to treatments (12). We can 
additionally elucidate that the response of tumors in vivo to β–Lapachone (i.p. with 50 
mg/kg) combined with ionizing radiation (20 Gy) caused tumor growth delays when 
compared to individual treatments alone. As such, the combined effects were apparently 
greater than additive. However these benefits vanished when consecutive tumor 
fractionated studies showed no synergistic benefit to fractionated treatments when 
compared to a single treatment, moreover, the tumor delaying effect was surprisingly 
even less than additive. Based on subsequent western blot studies where relative 
concentrations of NQO1 were observed, it shows a decline in its concentration following 
combined treatments of β-lap and irradiation, in a treatment comparable to one of the 
fractionated treatments. Future studies are needed to better characterize NQO1 levels, not 
only to observe possible ways for its up-regulation, but to also observe its concentration 
in a post β– Lapachone and a combined β–Lapachone and radiation treated environment. 
However, based on what was observed, the synergy in cell lethality between β–
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Lapachone and therapeutic radiation appears to be best exploited when used in a single 
fraction, therefore putting it into consideration for used along with SBRT and SRS 
treatments. 
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6 Appendix 
 
 
6.1  Supplementary Figures 
 
 
 
Figure A1 Percent of A549 cells in different cell cycle phases after various 
treatments with 7.5 µM β–Lapachone and 4 Gy irradiation having 
various end time points. Percentage of cells in the different cycles 
were determined by Propidium Iodide intensity staining and 
calculated using the Dean-Jet-Fox mathematical model. Each data 
point represents an average minimum of 6 experiments with ± 1 
S.E.  
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Figure A2. Left: A Lapachone tree. Right: Bark extract from the Lapachone 
tree – used as a medicinal tea. (Wikipedia Commons Image 
Database) 
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Figure A3. Proposed mode of action for β–Lapachone’s cytotoxicity. 
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6.2  Radiation Dosimetry – TG 61 Work Sheet 
 
Calculating dose to water on phantom surface (61) 
 
 
